Aim: To evaluate the efficacy of Autologous Serum Therapy in patients with Chronic Urticaria. Material and methods: The inclusion criteria consisted of individuals aged over 18 years, with a duration of chronic urticaria exceeding 6 weeks, absence of any medical conditions, willingness to participate in weekly follow-up, and no use of steroids for a minimum of two weeks. A total of 140 patients underwent assessment, and 100 of them were enrolled in our research after obtaining informed written permission. Each patient was then issued a unique identifier, known as a PIN. ASST was performed on all 100 patients according to the following description. Results: ASST was positive in 42 patients (42%). Mean of MUTSS for ASST positive group and ASST negative group was 14.21±3.26 and 13.04±3.65 respectively. This difference is statistically significant (p=0.03). The mean of MUTSS post-treatment in ASST positive group as 4.11±1.34, whereas in negative group it was 6.76±1.31. This difference was statistically significant (p=0.013). Also mean difference in pre and post treatment MUTSS was significantly higher in ASST positive group as compared to ASST negative group (p=0.001) indicating higher response of therapy in ASST positive group. Conclusion: Out of the whole group of patients with chronic urticaria, 42% were classified as having the autoimmune type. Among these individuals, around half saw a positive response to autologous serum treatment. The average value of MUTSS for the ASST positive group was 14.21±3.26, whereas for the ASST negative group it was 13.04±3.65. This difference is statistically significant, with a p-value of 0.03. The mean MUTSS post-treatment in the ASST positive group was 4.11±1.34, whereas in the negative group it was 6.76±1.31. This difference was statistically significant (p=0.013).